NKTR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NK

Mkt Cap

$1.22B

Volume

629.78K

Next Earnings

November 5th

Loading chart

NK

NKTRNektar Therapeutics

NKTR

Pay with—

Available Balance0.00

NK

Mkt Cap

$1.29B

Volume

629.77K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 15, 2026

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 LaunchProsight Management increased its stake in Nektar Therapeutics by 180,367 shares ($10.27 million) in Q1 2026, making it the fund's largest position at 8.67% of AUM. The biotech company's stock has surged nearly 600% over the past year as it prepares to launch Phase 3 trials for rezpegaldesleukin, its experimental autoimmune disease treatment. With over $1 billion in liquidity, Nektar is well-positioned financially, though success depends on late-stage clinical trial outcomes.The Motley Fool · May 23, 2026

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Nektar Therapeutics alleging that company defendants made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely had a significant negative impact on trial results and overall integrity. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case.GlobeNewswire Inc. · May 5, 2026

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & KorsinskyNektar Therapeutics faces a securities class action lawsuit alleging the company misrepresented enrollment standards in its REZOLVE-AA Phase 2b clinical trial. Four patients with major eligibility violations were included in the trial, including two with unstable alopecia areata diagnosed less than six months prior and two who began treatment before completing the required eight-week medication washout period. The trial's primary endpoint missed statistical significance with these ineligible patients included but met significance when they were excluded. The company had made repeated assurances about rigorous enrollment protocols across press releases, earnings calls, and SEC filings from February through November 2025. The lead plaintiff deadline is May 5, 2026.GlobeNewswire Inc. · May 5, 2026

NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5thA class action lawsuit has been filed against Nektar Therapeutics for allegedly making false statements about its REZOLVE-AA trial. The company failed to disclose that trial enrollment did not follow protocol standards, and four ineligible patients were included. When Nektar announced the trial's failure to reach statistical significance on December 16, 2025, its stock fell 7.77%. Investors who purchased shares between February 26, 2025 and December 15, 2025 can join the lawsuit by May 5, 2026.GlobeNewswire Inc. · May 4, 2026

NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTRA securities class action lawsuit has been filed against Nektar Therapeutics for allegedly making false and misleading statements regarding the REZOLVE-AA trial. The lawsuit claims the company failed to disclose that enrollment in the trial did not follow applicable instructions and protocol standards, which negatively impacted trial results and integrity. Investors who purchased NKTR securities between February 26, 2025 and December 15, 2025 may be eligible for compensation. The lead plaintiff deadline is May 5, 2026.GlobeNewswire Inc. · May 4, 2026

ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGCRosen Law Firm has filed class action lawsuits against Regencell Bioscience Holdings Limited, Globant S.A., and Nektar Therapeutics on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false and/or misleading statements regarding market manipulation vulnerabilities, regulatory risks, and financial exposure. Investors have until June 23, 2026 to move the court to serve as lead plaintiff.GlobeNewswire Inc. · May 4, 2026

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Nektar Therapeutics alleging that the company made materially false and misleading statements regarding its REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely had a significant negative impact on trial results and overall integrity. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case.GlobeNewswire Inc. · May 1, 2026

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Nektar Therapeutics alleging that company defendants made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims enrollment in the trial did not follow applicable protocol standards, which likely negatively impacted trial results and overstated the trial's integrity and prospects. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case, with a lead plaintiff deadline of May 5, 2026.GlobeNewswire Inc. · Apr 28, 2026

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitNektar Therapeutics faces a securities fraud class action lawsuit after its Phase 2b REZOLVE-AA trial for alopecia areata treatment failed to reach statistical significance. The company allegedly failed to disclose that trial enrollment did not follow protocol standards, leading to a 7.8% stock price decline on December 16, 2025. Investors have until May 5, 2026 to file a lead plaintiff motion.GlobeNewswire Inc. · Apr 24, 2026

to start trading

NK

NKTRNektar Therapeutics

NKTR

Pay with—

Available Balance0.00

Your PositionYou don't own any NKTR yet.

Related Tickers

Earnings